

ASX Announcement

29<sup>th</sup> December 2023

## PLACEMENT CLEANSING NOTICE

Genetic Signatures Limited (ASX: GSS, the “Company”) advises that it has today issued 21,510,899 fully paid ordinary shares (“New Shares”) in accordance with the Company’s ASX announcement of 21 December 2023 regarding the Company successfully raising a total of approximately \$8 million (before costs) in a placement to sophisticated and institutional investors (“Placement”) by the issue of New Shares at the offer price of \$0.37 per New Share.

The Company gives notice that:

- (a) the New Shares were issued without disclosure under Corporations Act 2001 (Cth) (“Corporations Act”);
- (b) this notice is being given under Section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice the Company has complied with:
  - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. sections 674 and 674A of the Corporations Act;
- (d) as at the date of this notice there is no excluded information (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

– ENDS –

### Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**  
Managing Director and  
Chief Executive Officer  
[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)  
T: +61 (0)2 9870 7580

**Karl Pechmann**  
Chief Financial and Operating Officer  
and Company Secretary  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.